Gregg Goldin, MD
Radiation Oncology · Raleigh, NCNPI 1982830782
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by AstraZeneca at 51.2% of the total. Reporting peaked in 2024 at $1,050 and has fallen 97.2% since, to $29 in 2025.
Across 22 payments — averaging $93.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Johnson & Johnson$290
- Zap Surgical Systems, Inc.$199
- Brainlab, Inc.$190
- Sirtex Medical Inc$104
- Novartis$69
- plus $149 from 5 others
What the payments were for
- Consulting fees$1,05051%
- Food & beverage$92645%
- Education$764%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,050 |
| Johnson & Johnson | 8 | $290 |
| Zap Surgical Systems, Inc. | 1 | $199 |
| Brainlab, Inc. | 2 | $190 |
| Sirtex Medical Inc | 1 | $104 |
| Novartis | 1 | $69 |
| Blue Earth Diagnostics | 2 | $49 |
| Novocure Inc. | 2 | $34 |
| Abbott | 1 | $29 |
| GE HealthCare | 1 | $20 |
| Elekta, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,050
- Zap-X$199
- SIR-Spheres Microspheres$104
How this compares
$2,052 in reported general payments places this provider in the 80th percentile of 199 radiation oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 15 | $41,031 |
| Tamsulosin Hcl | 20 | $374 |
| Memantine Hcl | 11 | $152 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Raleigh
- Andrew WangChapel Hill$118K
- Volker StieberWinston Salem$99K
- Lewis SulmanDurham$54K
- Michael PapagikosWilmington$51K
- William LeeDurham$37K
- Matthew ManningGreensboro$33K
- Michael ChanWinston Salem$32K
- John KirkpatrickDurham$29K
- John HeinzerlingCharlotte$29K
- Brian CzitoDurham$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.